Physician profile
David Jacob Hermel
NPI 1043673734
$59,202.20
in general payments reported to CMS, 2019-2025
62 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $693 · 2021: $1,435 · 2022: $1,808 · 2023: $4,245 · 2024: $7,847 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Honoraria: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,287 · Food and Beverage: $8,289 · Education: $729 · Travel and Lodging: $420 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,381.00 |
| Honoraria | $13,040.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,286.93 |
| Food and Beverage | $8,289.34 |
| Education | $728.75 |
| Travel and Lodging | $420.00 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $13,704.17 | 2020-2025 | Xpovio |
| Pfizer INC. | $12,802.68 | 2019-2025 | |
| Janssen Biotech, INC. | $7,073.42 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $6,201.36 | 2019-2025 | Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $2,897.63 | 2020-2025 | Opdivo, Abecma, Opdualag |
| Rigel Pharmaceuticals, INC. | $2,547.46 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Servier Pharmaceuticals LLC | $1,960.00 | 2024 | |
| Incyte Corporation | $1,544.92 | 2020-2025 | Jakafi |
| Alexion Pharmaceuticals, INC. | $1,401.79 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $939.86 | 2020-2025 | Vanflyta, Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $848.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $600.82 | 2019-2022 | |
| Abbvie INC. | $582.40 | 2020-2025 | |
| Lilly USA, LLC | $467.33 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Genzyme Corporation | $457.46 | 2019-2024 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $452.30 | 2021-2023 | Adcetris |
| Aveo Pharmaceuticals, INC. | $297.26 | 2021-2024 | |
| Sobi, INC | $295.60 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.61 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Novartis Pharmaceuticals Corporation | $263.39 | 2019-2025 | |
| Genentech USA, INC. | $234.03 | 2019-2025 | Tecentriq, Columvi, Venclexta |
| Pharmaessentia USA Corporation | $209.30 | 2023-2025 | Besremi |
| Celgene Corporation | $200.41 | 2022-2025 | Reblozyl, Opdivo, Onureg |
| Ipsen Biopharmaceuticals, INC | $199.36 | 2019-2024 | Onivyde, Tazverik, Somatuline Depot |
| Eisai INC. | $198.39 | 2019-2025 | |
| Beigene USA, INC. | $173.40 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $153.90 | 2022-2025 | Libtayo |
| Glaxosmithkline, LLC. | $146.80 | 2020-2024 | Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $141.33 | 2019-2025 | |
| Kite Pharma, INC. | $131.17 | 2020-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $124.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.05 | 2025 | Jardiance |
| Emd Serono, INC. | $118.73 | 2019-2024 | Bavencio |
| Dova Pharmaceuticals | $109.88 | 2021 | |
| Array Biopharma INC | $109.26 | 2023-2025 | Xalkori, Lorbrena, Braftovi |
| Astellas Pharma US INC | $96.99 | 2022-2025 | Xospata, Vyloy, Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $96.36 | 2019-2023 | Imbruvica |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Gilead Sciences, INC. | $83.69 | 2025 | Trodelvy |
| Taiho Oncology, INC. | $81.97 | 2023-2024 | |
| Exelixis INC. | $81.71 | 2022-2023 | Cabometyx |
| Tersera Therapeutics LLC | $68.62 | 2024-2025 | Quzyttir, Xermelo |
| Foundation Medicine, INC. | $56.90 | 2020-2023 | |
| Stemline Therapeutics INC. | $53.62 | 2023-2024 | Orserdu |
| Coherus Oncology, INC. | $51.02 | 2024-2025 | Loqtorzi, Udenyca |
| Cti Biopharma Corp. | $50.59 | 2022-2023 | Vonjo |
| Genmab U.S., INC. | $38.40 | 2023-2024 | Epkinly |
| Blueprint Medicines Corporation | $36.43 | 2021-2024 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $31.20 | 2023 | Empaveli |
| Janssen Pharmaceuticals, INC | $30.09 | 2019-2023 | Xarelto |
| Caris Mpi, INC. | $28.68 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $27.98 | 2022 | |
| Beone Medicines USA, INC. | $26.95 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $26.26 | 2023 | Krazati |
| Dendreon Pharmaceuticals LLC | $26.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.69 | 2023 | |
| Tempus Ai, INC | $19.69 | 2024 | |
| Tesaro, INC. | $15.70 | 2019 | |
| Shorla Oncology INC. | $14.96 | 2025 | |
| Puma Biotechnology, INC. | $13.60 | 2025 | |
| Csl Behring | $13.41 | 2024 | Idelvion, Afstyla |
| Clovis Oncology, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hermel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.